About this trial
This is a randomised, active-controlled, open-label study of pembrolizumab (Pembro) given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in treatment naïve participants with newly diagnosed Stage III/IVA, resectable, locoregionally advanced, head and neck squamous cell carcinoma (LA-HNSCC). Participants will receive either pembrolizumab given before surgery and after surgery in combination with radiotherapy (with or without cisplatin) or radiotherapy (with or without cisplatin) given after surgery alone.
Patient Profile
Patients with resectable locoregionally advanced Head and Neck Squamous Cell Carcinoma
Where’s this trial being run?
St James’s Hospital and St Luke’s Radiation Oncology Network @ St Luke’s Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.
Print this pageFor more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | MK-3475-689 |
|---|---|
| Number: | 19-39 |
| Full Title: | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC) |
| Principal Investigator: | Dr Cliona Grant |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | Merck Sharp & Dohme LLC |
| Recruitment Started: |
Global: Dec 2018 Ireland: March 2021 |
| Global Recruitment Target: | 704 |
|---|---|
| Ireland Recruitment Target: | 5 |